Results for tag: "Non Hodgkin Lymphoma Clinical Trial"

The Non Hodgkin Lymphoma Clinical Trial market is a subset of the larger Lymphoma Drugs market. It focuses on clinical trials for drugs used to treat Non Hodgkin Lymphoma (NHL). These trials are conducted to assess the safety and efficacy of the drugs, as well as to determine the optimal dosage and administration. The trials are conducted in phases, with Phase I trials typically involving a small number of patients and Phase III trials involving a larger number of patients. The results of these trials are used to determine whether the drug should be approved for use in the treatment of NHL. The Non Hodgkin Lymphoma Clinical Trial market is highly competitive, with many companies vying for a share of the market. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more